Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Published: 04 August 2023
New trends in brain tumor immunity with the opportunities of lymph nodes targeted drug delivery.
Yangzhi Qi, Wei Xiong, Qianxue Chen, Zhifei Ye, Cailei Jiang, Yan He & Qingsong Ye
lymph nodes (LNs)
'Nah I'm not accepting that' The inspiring Tracy Verblis joined @SineadBrassil on 11-1 to discuss her battle with a rare form of brain cancer known as the 'Terminator'
— LMFM RADIO (@LMFMRADIO) June 15, 2023
Listen back here https://t.co/yOYUAOhvEG pic.twitter.com/AuuRvASdvY
Help Joel Live Longer.
Joel received the devastating diagnosis of glioblastoma around Sept.1, 2019.
On the 25th March 2021 Joel had his very first dose of Dendritic Cell Vaccine, (DCVax-L).
On the 5th of May 2021 Joel had his fourth and final dose of Dendritic Cell Vaccine, (DCVax-L), at Kings College Hospital in London, with Professor Keyoumars Ashkan.
Update – July 2023
Doc logic,
I have a different opinion.
I think FDA mandated a partial clinical hold on recruitment because the data showed that the survival rate was greater in both arms (placebo (cross-over) and treatment arm) than that observed in similar studies in patients with GBM.
I believe the DSMB reviewed an initial analysis (March 2015) of the unblinded data and concluded that the trial was unlikely to meet its primary PFS endpoint, even though the prespecified criteria for termination of the trial had not been met. We learned that while the trial was underway, Pseudo-progression (PsPD) became recognized as major issue—difficulty distinguishing real vs. PsPD.
But the unblinded data also showed improved (health) survival outcomes in both arms and no treatment emergent safety issues.
IMO, the FDA wanted to find out what was going on and recommended to pause new recruitment in the ongoing clinical DCVax-L trial while additional data would be collected over an 18-month period.
Enrollment of subjects already in screening was not affected and subjects enrolled continued treatment.
On Febr.6, 2017 the FDA "partial clinical hold" has been lifted because patients with newly diagnosed and recurrent glioblastoma (GBM) brain cancer had an increase in median survival and extended survival when treated with dendritic cell vaccination (DCVax-L), according to findings from the ongoing phase 3 DCVax-L clinical trial. IMO
The Danish Dude,
I am truly sorry. My deepest condolences to you and your family.
Our loving mom, grandmother and mother in law, passed away this morning in an uneven and way to meaningless battle.
— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) July 28, 2023
Finally you found peace 🙏🏻
Thanks for everything.
We love you so much!
Bye mom!
❤️ pic.twitter.com/vblNeeKq14
@biggercapital you see the post regarding “18-24 months” for DCVax approval from the mother of a patient with gbm…a major stakeholder in $NWBO told her this. I own over 2 million shares and willing to join if you become take a activist stance. If true18-24 months is unacceptable
— Fireman02360 (@fyre02532) July 29, 2023
Exactly. Thanks biosectinvestor.
Flipper44,
She is just a mum trying to save Hannah’s life.
Hannah is her funny little darling daughter and she would go to the very ends of the earth for her, like any mum would..
Her family need support before they literally run out of time.
They can’t wait for approval given the illness they are facing.
She is a desperate mum in a desperate situation. Someone she believed to be trustworthy, told her that approval could take 18-24 months. It’s not from Professor Ashkan Keyoumars or one of the stakeholders you mention.
She knows next to nothing about DCVax-L and she is so grateful for the information I share with her.
You're right, looking at 18 to 24 months makes zero sense.
https://www.justgiving.com/crowdfunding/gail-iredale?fbclid=IwAR1xSsJTu_TGlwG2fUTYe2Lps8gL2JpSJ53Vs94DbSHERnCcCXTIvgnVWJs
Stonkmaster,
I asked Hannah' s mum.
Here is her reply:
3 weeks ago:
Thanks for sharing Danish Dude.
prepare to be surprised
— Ted Nesi (@TedNesi) July 29, 2023
Facebook-JustGiving
1 day ago
abc1212,
10 days ago I asked Jui Chen if there would be a recorded version of Linda Liau's presentation?
Reply:
Dr June M Raine DBE
Chief Executive’s perspective on the year.
📰 Our Annual Report for 2022/23 is out now.
— MHRAgovuk (@MHRAgovuk) July 19, 2023
From cutting-edge science and supporting innovation to criminal enforcement and improving patient access, read all about the MHRA’s work over the past year.
Check out our Annual Report here 👉 https://t.co/X0jxsQJFWV pic.twitter.com/OLk30JECrA
📰 Our Annual Report for 2022/23 is out now.
— MHRAgovuk (@MHRAgovuk) July 19, 2023
From cutting-edge science and supporting innovation to criminal enforcement and improving patient access, read all about the MHRA’s work over the past year.
Check out our Annual Report here 👉 https://t.co/X0jxsQJFWV pic.twitter.com/OLk30JECrA
Thanks pgsd for sharing.
Dr June M Raine DBE
Chief Executive’s perspective on the year.
💊 729 new medicines approved in UK this year!
— MHRAgovuk (@MHRAgovuk) July 21, 2023
👨👩👧 Over the past 12 months, we’ve worked hard to assess the safety, quality and effectiveness of new medicines to enable access to UK patients.
To learn more, check out our Annual Report 👉 https://t.co/X0jxsQJFWV pic.twitter.com/UlmqLEj3mz
ATLnsider,
IMO, BLAs are submitted in a format known as the Electronic Common Technical Document (eCTD). The eCTD is organized into five modules. Module 1 is country or region specific and contains the information that is unique to a region. Module 2 contains summary documents for Modules 3–5.(Quality- Safety- Efficacy)
Good to see that “ Use of External Control Data in Brain Tumor Clinical Trials” is on National Brain Tumor Society’s agenda.
Early train, DC, making progress in clinical trials for #Glioblastoma. Today was a good day. Total class from @NBTStweets pic.twitter.com/JrVbXIY4tQ
— Vijay Agarwal (@drvijay_agarwal) July 20, 2023
GBM AGILE leadership attending the @NBTStweets Glioblastoma Awareness Day reception.#GBMDay is a day dedicated to raising awareness for patients and remembering why we do the work that we do: to speed the discovery and development of treatments for this terrible disease. Thank… pic.twitter.com/N6b9qpbVoZ
— Global Coalition for Adaptive Research (@GCAResearch) July 20, 2023
What you need to know about glioblastoma.
Glioblastoma is the most common and deadly malignant primary brain tumour in adults. @sheilasinghlab shares recent advancements in #glioblastoma research that may bring hope for patients. #GlioblastomaAwarenessDay @CDCR_Mac
— McMaster Health Sciences (@machealthsci) July 19, 2023
LEARN MORE: https://t.co/tQFLdKiyFF pic.twitter.com/TXqkaXUP3J
Survaxm Vaccine For Glioblastoma.
Presented as part of the Musella Foundations' Brain Tumor Webinar Series.
Speaker: Michael Ciesielski, PhD, Chief Executive Officer of MimiVax, LLC
Dcvax mentioned in Q&A part.
Excellent DD, thank you tunnelvisionofplenty!
Update Tracy (leukapheresis procedure on June 12, 2023)
Today June 18, 2023
Thank you to our #GBMDay sponsors. Because of your generous support, we are able to shine a light on the urgent, unmet needs of the #glioblastoma (#GBM) community: https://t.co/T2XEwjPSqr pic.twitter.com/CfrNjFodXM
— National Brain Tumor Society (@NBTStweets) July 17, 2023
Thanks for the info, Baxers. Much appreciated.
Professor Linda Liau’s Lectures in Taiwan.
July 18,2023
The Department of Neurological Institute
Taichung Veterans General Hospital,Taiwan.
Professor Linda Liau : “Immunotherapy for malignant brain tumor”.
July 25,2023
College of Medicine
National Cheng Kung University
No. 1 University Rd, Tainan, Taiwan
Special Lecture by Faculty of Medicine, July 25, 2023, Linda M. Liau, MD, PhD, MBA - "Current advances in brain tumor immunotherapy and vaccines"
Recently,
June 17, 2023
Taiwan Top Science Student Project
GAIA STEM Lectures Series 24 – Linda Liau- Personalized Immunotherapy for Brain Cancer.
In February 2019, Shenell Malloy was enjoying a Super Bowl weekend getaway with friends in Cabo San Lucas in Mexico. She’d been feeling brief instances of numbness and tingling on one side of her body, but she didn’t pay much attention at first. After all, she was healthy and only 36, a loving wife and mother with a busy and active life. However, when she arrived in San Diego, she had a full-blown seizure.
After many brain scans, MRIs, and blood work, doctors confirmed an unidentified brain abnormality. She got a second opinion from the UCLA Neurology Department, where her surgeon, the brilliant Dr. Linda Liau, performed a six-hour operation the very next day. That surgery gave us the answer: Shenell had a brain tumor, a grade 4 glioblastoma.
ATLnsider,
the DCVax-L (ATL-DC) along with poly-ICLC + Pembrolizumab (Keytruda) combination trial is a window of opportunity trial.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873
Here is an interesting read:
The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I-III Studies.
https://link.springer.com/article/10.1007/s11912-023-01433-1
#Glioblastoma is a very aggressive brain tumor that can cause life-threatening effects.
— UCLA Neurology (@UCLANeurology) July 12, 2023
Drs. PhiOanh Leia Nghiemphu and Timothy Cloughesy discuss clinical research trial findings for glioblastoma treatment.https://t.co/HpjeFKXhdg pic.twitter.com/gRegY4cxmR
It’s really a trial that’s a window of opportunity trial without changes in dosing like a traditional Phase 1 trial. It’s not a dose finding trial and also not an efficacy trial. Please realize the “phase” here doesn’t matter. Focus on the purpose of the trial.
— PhiOanh "Leia" NghiemPhu, MD (@Leia_N_MD) July 6, 2023
Excellent thoughts hyperopia!
Here is an interesting read:
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1226841/full
July 11, 2023
Bringing function to the forefront of cell therapy: how do we demonstrate potency?
Mark W. Lowdell and Ben Weil
Help for Hannah
1 day ago
·
My dear #nwbo $NWBO friends.
— Johnny Boy Zoots (@JohnnyBoyZoots) July 8, 2023
We believe. We support if we can.
I can. I did.
I've #justdonated to save Hannah's Life with the DC-Vax which is not available on the NHS Please share/Donate/Send Love x. Donate on @justgiving and help raise £150000 https://t.co/UQ9KMVYTsU
hyperopia,
Thank you as always for your incredible work for this board.
Great summary, thanks Chiugray!
Thanks abeta for sharing Hannah's story!
Keeping everything crossed that they can raise the money for her treatment!
https://www.justgiving.com/crowdfunding/gail-iredale?utm_term=zxmewna3z&fbclid=IwAR1so6BL1BGU4a5K9LJuaALIOodkp0qAqQ259eCNibkIxE_1H7yIbScNJRI
$NWBO people. Hannah has GBM4 & is now post resection with her tumour stored correctly by Ashkan but the crux of the matter is they need to raise £150k to begin getting the DCVax made. They are at £30k so far...
— Tommy Bax 🇬🇧 🇹🇼 (@TommyBaxendale) July 7, 2023
Dig deep people, her life is on the line!https://t.co/b2EvJbKSdk
Happy Birthday Springbok80.I wish you have not just a great and wonderful day but also a wonderful year throughout.